JI 101

Drug Profile

JI 101

Alternative Names: CGI-1842; JI-101

Latest Information Update: 30 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CGI Pharmaceuticals
  • Developer Jubilant Innovation; University of Utah
  • Class Antineoplastics
  • Mechanism of Action Angiogenesis inhibitors; EphB4 inhibitors; Platelet-derived growth factor beta receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 31 Jan 2012 Jubilant Innovation completes a phase I/II trial in Solid tumours in US (NCT00842335)
  • 16 Nov 2010 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2010)
  • 19 Nov 2009 Interim adverse events data from a phase I trial and pharmacodynamic data from preclinical trials in Cancer presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top